Ann Dermatol.  2016 Feb;28(1):113-114. 10.5021/ad.2016.28.1.113.

Treatment of Classic Kaposi's Sarcoma Showing a Discretely Scattered Distribution with Intralesional Vinblastine Injections

• Kim BR
• Park JT
• Byun SY
• Kwon SH
• Huh CH

• KMID: 2429493
• DOI: http://doi.org/10.5021/ad.2016.28.1.113

Abstract

No abstract available.

MeSH Terms

Sarcoma, Kaposi*
Vinblastine*
Vinblastine

Figure

• 

  Fig. 1 Clinical presentation of a discretely scattered classic Kaposi's sarcoma. (A) Widely distributed red-purple papules and plaques evident before treatment, and (B) complete regression of the tumors 5 weeks after treatment with intralesional vinblastine injections showing only residual hyperpigmentation.

• 

  Fig. 2 Immunohistochemical evaluation of classic Kaposi's sarcoma specimens. (A) Endothelial cells of the abnormal vessels staining positively for cluster of differentiation 31; (B) Spindle cells staining positively for Friend leukemia virus integration-1; and (C) Spindle cells staining focally positively for human herpesvirus-8 (×200 for all panels).

Reference

1. Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcomaassociated herpesvirus (human herpesvirus 8). Mayo Clin Proc. 2002; 77:941–949.

2. Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol. 2004; 87:146–151.

3. Kim SY, Kim DH, Lee HJ, Seo YJ, Lee JH, Lee Y. Treatment of disseminated classic type of Kaposi's sarcoma with paclitaxel. Ann Dermatol. 2011; 23:504–507.

4. Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS. Eur J Cancer B Oral Oncol. 1995; 31B:280–285.

5. Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol. 2013; 68:313–331.